Cefaclor safety profile: a ten-year review.
Hyslop
D L
DL
Chemotherapy Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002433:Cefaclor / Q000009:adverse effects* / Q000627:therapeutic use; D002506:Cephalexin / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged
D002433:Cefaclor; D002506:Cephalexin